Compensation award — excluded from discretionary-purchase analysis.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
View the official recordSEC Form 4 — Statement of Changes in Beneficial OwnershipAll the details
Dates, kept separate
Transaction date
Feb 10, 2026
Reporting period
Not applicable
Filed with the SEC
Feb 12, 2026
CEOGrant / award
Context
Classification
grant award
Code A — grant or award
Planned / mechanical clue
Footnote references vesting of compensation awards
Only flagged when a footnote says so; never inferred
Source receipt
Record ID
0001699488-26-000002
Filed / recorded
Feb 12, 2026, 9:30 PM UTC
Added to OQRO
Oct 6, 2026, 10:35 PM UTC
Parser
form4-xml-v2
Data quality
Verified: identifiers matched exactly
Issuer
COLLEGIUM PHARMACEUTICAL, INC
Issuer CIK
1267565
Ticker
COLL
Reporting person
Vikram Karnani
Relationship
Director, Officer
Officer title
President and CEO
Security
Common Stock
Table
Non-derivative (Table I)
Transaction date
Feb 10, 2026
Transaction code
A
Shares / units
32,531
Price per share
$0.00
Acquired / disposed
Acquired (A)
Shares owned after
209,160
Ownership form
Direct
Amendment
No
Footnotes from the filing
Effective February 10, 2026, the Compensation Committee of the Board of Directors of the Issuer determined that performance-vesting criteria were met with regard to an aggregate of 32,531 performance share units ("PSUs") granted in the Issuer's 2025 fiscal year.